Patents Assigned to D. E. Shaw Research, LLC
-
Patent number: 12632623Abstract: A predictive system may access a set of physical structures corresponding to a physical system. Each physical structure representative of a configuration. The predictive system may encode the accessed physical structures to produce a set of encoded physical structures by encoding, for each accessed physical structure, a position of each constituent unit of the physical system within the accessed physical structure. The predictive system may train a machine-learned model using the encoded physical structures. The predictive system may retrain the machine-learned model by iteratively: accessing a set of two or more candidate physical structures, determining a first energy difference among the set of candidate physical structures, obtaining a second energy difference between a set of physical structures corresponding to the set of candidate physical structures using a method to calculate reference energy values.Type: GrantFiled: August 23, 2024Date of Patent: May 19, 2026Assignee: D. E. Shaw Research, LLCInventors: Paul Maragakis, Andreas Kraemer, James P. Roney, Peter Skopp
-
Patent number: 12581252Abstract: The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of PI3K? enzymes with the compounds and compositions of formula I-1. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with PI3K? signaling with the compounds and compositions of formula I-1.Type: GrantFiled: April 29, 2021Date of Patent: March 17, 2026Assignees: Relay Therapeutics, Inc., D. E. Shaw Research, LLCInventors: Alessandro Boezio, Lucian V. Dipietro, Hakan Gunaydin, Thomas H. McLean, Levi Charles Thomas Pierce, Fabrizio Giordanetto, Yakov Pechersky, Megan Bertrand-Laperle, Alexandre Larivee, Kashif Tanveer, Michael Paul DeNinno, Tarek Mohamed
-
Patent number: 12522605Abstract: The present disclosure relates to novel compounds of formula I-1, and pharmaceutical compositions thereof, and methods for inhibiting the activity of FGFR enzymes with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with FGFR signaling with the compounds and compositions of the disclosure.Type: GrantFiled: May 12, 2020Date of Patent: January 13, 2026Assignees: Relay Therapeutics, Inc., D. E. Shaw Research, LLCInventors: Bakary-Barry Touré, Heike Schoenherr, Alexander M. Taylor, Fabrizio Giordanetto, Demetri T. Moustakas, Thomas H. McLean, Brandi M. Hudson, Mary M. Mader, Pelin Ayaz, Dina A. Sharon, Ravi Kurukulasuriya, Alessandro Boezio
-
Patent number: 12511482Abstract: A system is disclosed for encoding a data string of a first modality into a hierarchical tokenized representation for processing by a text-based deep neural network (DNN) trained on a second modality. The data string comprises multiple units, each having one or more attributes. Each attribute is represented in the tokenized string as a sequence of hierarchical tokens, with a first hierarchical token encoding one or more most significant bits and a subsequent hierarchical token encoding one or more less significant bits. The DNN processes the data string bidirectionally, across the sequence of units and within the token hierarchy, to select tokens that capture attribute information. The selected hierarchical tokens output by the DNN from a representation of the original data string that preserves attribute detail while enabling cross-modal processing using models trained on text.Type: GrantFiled: August 22, 2025Date of Patent: December 30, 2025Assignee: D. E. Shaw Research, LLCInventors: Paul Maragakis, Andreas Kraemer, James P. Roney, Peter Skopp
-
Patent number: 12219327Abstract: The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of PI3K-? enzymes with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with PI3K-? signaling with the compounds and compositions of the disclosure.Type: GrantFiled: June 9, 2023Date of Patent: February 4, 2025Assignees: Relay Therapeutics, Inc., D. E. Shaw Research, LLCInventors: Lucian V. Dipietro, Kelley C. Shortsleeves, Thomas H. Mclean, Alexandre Larivee, Fabrizio Giordanetto, André Lescarbeau, Alessandro Boezio, Hanmo Zhang
-
Patent number: 12217834Abstract: Discovering molecules (which may be known or may never have been cataloged or ever synthesized) that have desired characteristics is addressed using a machine learning approach. As compared to a brute-force search of a database of known molecules, which may not be computationally feasible, the present machine learning approach renders identification of both known and unknown molecules computationally tractable. Furthermore, the computational effort is largely shifted to training of the machine learning system using a database of known molecules, and the generation of molecules to match any particular characteristics requires relatively little computation. The molecules using the present approach may be further studied, for example, with computer-based simulation or after physical synthesis using biological experimentation to ultimately yield useful chemical compounds.Type: GrantFiled: May 29, 2020Date of Patent: February 4, 2025Assignee: D. E. Shaw Research, LLCInventors: Paul Maragakis, Hunter Nisonoff, Peter Skopp, John Salmon
-
Patent number: 11701354Abstract: Cellular biological activities are tightly controlled by intracellular signaling processes initiated by extracellular signals. Protein tyrosine phosphatases, which remove phosphate groups from tyrosine phosphorylated signaling molecules, play equally important tyrosine roles as protein kinases in signal transduction. SHP-2, a cytoplasmic SH2 domain containing protein tyrosine phosphatase, is involved in the signaling pathways of a variety of growth factors and cytokines. Recent studies have clearly demonstrated that this phosphatase plays an important role in transducing signal relay from the cell surface to the nucleus, and is a critical intracellular regulator in mediating cell proliferation and differentiation.Type: GrantFiled: September 28, 2018Date of Patent: July 18, 2023Assignees: D. E. Shaw Research, LLC, Relay Therapeutics, Inc.Inventors: Alexander M. Taylor, W. Patrick Walters, Mark Andrew Murcko, Fabrizio Giordanetto, Eric Therrien, Sathesh Bhat, Markus Kristofer Dahlgren
-
Patent number: 11629145Abstract: The present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the invention. The present invention further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds ad compositions of the invention.Type: GrantFiled: October 24, 2017Date of Patent: April 18, 2023Assignees: D. E. Shaw Research, LLC, Relay Therapeutics, Inc.Inventors: Fabrizio Giordanetto, Jack Benjamin Greisman, Paul Maragakis, Alexander M. Taylor, Lucian V. Dipietro, Elizabeth H. Kelley, André Lescarbeau, Mark Andrew Murcko, Levi Charles Thomas Pierce, Kelley C. Shortsleeves, W. Patrick Walters, Sathesh Bhat, Eric Therrien, Markus Kristofer Dahlgren
-
Patent number: 11591336Abstract: The present disclosure relates to compounds of formula (I) and pharmaceutical compositions thereof and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds and compositions of the disclosure.Type: GrantFiled: May 25, 2018Date of Patent: February 28, 2023Assignees: D. E. Shaw Research, LLC, Relay Therapeutics, Inc.Inventors: Alexander M. Taylor, André Lescarbeau, Elizabeth H. Kelley, Kelley C. Shortsleeves, Lucian V. DiPietro, W. Patrick Walters, Mark Andrew Murcko, Levi Charles Thomas Pierce, Yong Tang, Fabrizio Giordanetto, Jack Benjamin Greisman, Paul Maragakis, Sathesh Bhat, Markus Kristofer Dahlgren, Eric Therrien
-
Publication number: 20230023559Abstract: A compound of Formula (I) or a pharmaceutically acceptable salt thereof is described, wherein the substituents are as defined herein. Pharmaceutical compositions comprising the same and method of using the same are also described.Type: ApplicationFiled: October 6, 2020Publication date: January 26, 2023Applicants: D. E. Shaw Research, LLC, D. E. Shaw Research, LLCInventors: Fabrizio GIORDANETTO, Morten Østergaard JENSEN, Vishwanath JOGINI, Roger John SNOW
-
Patent number: 11529348Abstract: Cellular biological activities are tightly controlled by intracellular signaling processes initiated by extracellular signals. Protein tyrosine phosphatases, which remove phosphate groups from tyrosine phosphorylated signaling molecules, play equally important tyrosine roles as protein kinases in signal transduction. SHP-2, a cytoplasmic SH2 domain containing protein tyrosine phosphatase, is involved in the signaling pathways of a variety of growth factors and cytokines. Recent studies have clearly demonstrated that this phosphatase plays an important role in transducing signal relay from the cell surface to the nucleus, and is a critical intracellular regulator in mediating cell proliferation and differentiation.Type: GrantFiled: September 28, 2018Date of Patent: December 20, 2022Assignees: D. E. Shaw Research, LLC, Relay Therapeutics, Inc.Inventors: Alexander M. Taylor, W. Patrick Walters, Mark Andrew Murcko, Fabrizio Giordanetto, Eric Therrien, Sathesh Bhat, Markus Kristofer Dahlgren
-
Patent number: 11529347Abstract: The present invention relates to novel compounds having the general formula: and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the invention. The present invention further relates to, but is not limited to, methods for suppressing tumor cell growth, ameliorating the pathogenesis of systemic lupus erythematosus, and the treatment of various other disorders, including Noonan syndrome, diabetes, neutropenia, neuroblastoma, melanoma, juvenile leukemia, juvenile myelomonocytic leukemia, chronic myelomonocytic leukemia, acute myeloid leukemia, and other cancers associated with SHP2 deregulation with the compounds and compositions of the invention, alone or in combination with other treatments.Type: GrantFiled: September 22, 2017Date of Patent: December 20, 2022Assignees: Relay Therapeutics, Inc., D. E. Shaw Research, LLCInventors: Brian K. Albrecht, Fabrizio Giordanetto, Jack Benjamin Greisman, Paul Maragakis, Alexander M. Taylor, W. Patrick Walters
-
Patent number: 11264120Abstract: A method for managing flow of particles into an array of pairwise-point-interaction-module includes receiving a first set of particles into a first queue. The first set is a proper subset of a second set of particles that comprises all particles that are to be passed into an array of pairwise-point-interaction-modules during a current time period. Prior to having received all particles from the second set, particles from the first set are allowed to pass from the first queue into the array.Type: GrantFiled: September 10, 2019Date of Patent: March 1, 2022Assignee: D. E. Shaw Research, LLCInventors: Ping Tak Peter Tang, J. P. Grossman, Brannon Batson, Ron Dror
-
Patent number: 7809535Abstract: A method for dynamics simulation involves maintaining quantities according to a floating point binary format quantized to a first precision lower than the precision supported by the floating point format. For example, although an IEEE floating point number can represent numbers with a precision of one part in 2^24, the quantities are quantized to a lower precision, such as one part in 2^22. Operations are applied to sets of the quantities by quantizing the intermediate results of the operations to the lower precision than the precision supported by the floating point format.Type: GrantFiled: October 1, 2007Date of Patent: October 5, 2010Assignee: D. E. Shaw Research, LLCInventor: Kevin J. Bowers
-
Patent number: 7809006Abstract: An approach to introducing adaptive routing into a communication approach for passing messages between nodes over links between the nodes includes forming virtual channels over the links of the system and defining a deterministic routing function over the virtual channels such that the deterministic routing function is deadlock free. Adaptive routing is then permitted at nodes using the existing virtual channels by introducing a constraint on the available virtual channels used to forward communication that arrives at a node for a particular destination. The constraint on the virtual channels is such that the adaptive system is also deadlock free.Type: GrantFiled: August 12, 2008Date of Patent: October 5, 2010Assignee: D. E. Shaw Research, LLCInventor: Brian Patrick Towles
-
Patent number: 7769571Abstract: An improved constraint approach reduces the energy drift rate to acceptable levels. In an embodiment of this approach, massively parallel constrained velocity Verlet NVE (constant particle number, constant volume, constant energy) MD simulations can be run using single precision arithmetic with very low energy drift (e.g., ˜1 Kelvin per microsecond simulated time) using large timesteps (e.g., 2.5 fs) for typical systems and MD force fields.Type: GrantFiled: October 1, 2007Date of Patent: August 3, 2010Assignee: D. E. Shaw Research, LLCInventor: Kevin J. Bowers
-
Patent number: 7526415Abstract: A method and a corresponding software and a system for processing a charge distribution according to a spreading function and a predefined operation are described.Type: GrantFiled: June 30, 2005Date of Patent: April 28, 2009Assignee: D. E. Shaw Research, LLCInventors: Yibing Shan, John Klepeis, Michael Eastwood, Ron Dror, David E. Shaw
-
Publication number: 20090046727Abstract: An approach to introducing adaptive routing into a communication approach for passing messages between nodes over links between the nodes includes forming virtual channels over the links of the system and defining a deterministic routing function over the virtual channels such that the deterministic routing function is deadlock free. Adaptive routing is then permitted at nodes using the existing virtual channels by introducing a constraint on the available virtual channels used to forward communication that arrives at a node for a particular destination. The constraint on the virtual channels is such that the adaptive system is also deadlock free.Type: ApplicationFiled: August 12, 2008Publication date: February 19, 2009Applicant: D. E. Shaw Research, LLCInventor: Brian Patrick Towles
-
Publication number: 20080082309Abstract: An improved constraint approach reduces the energy drift rate to acceptable levels. In an embodiment of this approach, massively parallel constrained velocity Verlet NVE (constant particle number, constant volume, constant energy) MD simulations can be run using single precision arithmetic with very low energy drift (e.g., ˜1 Kelvin per microsecond simulated time) using large timesteps (e.g., 2.5 fs) for typical systems and MD force fields.Type: ApplicationFiled: October 1, 2007Publication date: April 3, 2008Applicant: D. E. Shaw Research, LLCInventor: Kevin Bowers
-
Publication number: 20080082303Abstract: A method for dynamics simulation involves maintaining quantities according to a floating point binary format quantized to a first precision lower than the precision supported by the floating point format. For example, although an IEEE floating point number can represent numbers with a precision of one part in 2ˆ24, the quantities are quantized to a lower precision, such as one part in 2ˆ22. Operations are applied to sets of the quantities by quantizing the intermediate results of the operations to the lower precision than the precision supported by the floating point format.Type: ApplicationFiled: October 1, 2007Publication date: April 3, 2008Applicant: D. E. Shaw Research, LLCInventor: Kevin Bowers